全文获取类型
收费全文 | 6804篇 |
免费 | 567篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 230篇 |
妇产科学 | 129篇 |
基础医学 | 986篇 |
口腔科学 | 119篇 |
临床医学 | 885篇 |
内科学 | 1364篇 |
皮肤病学 | 61篇 |
神经病学 | 600篇 |
特种医学 | 174篇 |
外科学 | 643篇 |
综合类 | 110篇 |
一般理论 | 4篇 |
预防医学 | 765篇 |
眼科学 | 266篇 |
药学 | 443篇 |
中国医学 | 8篇 |
肿瘤学 | 527篇 |
出版年
2022年 | 54篇 |
2021年 | 95篇 |
2020年 | 61篇 |
2019年 | 90篇 |
2018年 | 105篇 |
2017年 | 71篇 |
2016年 | 99篇 |
2015年 | 121篇 |
2014年 | 165篇 |
2013年 | 219篇 |
2012年 | 271篇 |
2011年 | 330篇 |
2010年 | 185篇 |
2009年 | 148篇 |
2008年 | 258篇 |
2007年 | 313篇 |
2006年 | 325篇 |
2005年 | 289篇 |
2004年 | 280篇 |
2003年 | 228篇 |
2002年 | 260篇 |
2001年 | 230篇 |
2000年 | 240篇 |
1999年 | 169篇 |
1998年 | 77篇 |
1997年 | 67篇 |
1996年 | 65篇 |
1995年 | 68篇 |
1994年 | 55篇 |
1993年 | 53篇 |
1992年 | 159篇 |
1991年 | 184篇 |
1990年 | 150篇 |
1989年 | 179篇 |
1988年 | 134篇 |
1987年 | 152篇 |
1986年 | 160篇 |
1985年 | 140篇 |
1984年 | 114篇 |
1983年 | 79篇 |
1982年 | 54篇 |
1981年 | 59篇 |
1980年 | 67篇 |
1979年 | 94篇 |
1978年 | 62篇 |
1977年 | 55篇 |
1975年 | 51篇 |
1974年 | 53篇 |
1973年 | 56篇 |
1971年 | 53篇 |
排序方式: 共有7382条查询结果,搜索用时 0 毫秒
51.
Molecular cloning and characterization of the 78-kilodalton glucose-regulated protein of Trypanosoma cruzi. 总被引:3,自引:0,他引:3 下载免费PDF全文
R S Tibbetts I Y Kim C L Olson L M Barthel M A Sullivan A G Winquist S D Miller D M Engman 《Infection and immunity》1994,62(6):2499-2507
The protozoan Trypanosoma cruzi is the etiologic agent of Chagas' disease, an illness responsible for morbidity and death among millions of Latin Americans. Mice also develop this disease when infected with T. cruzi and are a useful model organism for the study of parasite-specific immune responses. To identify immunogenic T. cruzi antigens, serum from an infected mouse was used to isolate clones from a T. cruzi epimastigote cDNA expression library. One of these clones was found to encode the 78-kDa glucose-regulated protein (grp78), the endoplasmic reticular member of the 70-kDa heat shock protein (hsp70) family. Like the mammalian and yeast grp78s, the T. cruzi protein contains an endoplasmic reticular leader peptide and a carboxyl-terminal endoplasmic reticular retention sequence. T. cruzi grp78 is encoded by a tandemly arranged family of three genes located on a chromosome of 1.6 Mb. The effects on grp78 expression of heat shock and tunicamycin treatment, the latter of which specifically stimulates mammalian grp78, were investigated. While the level of the grp78 protein remained constant under all circumstances, grp78 mRNA was unaffected by heat shock but induced fivefold by tunicamycin. Finally, we found that grp78 is the most immunogenic of the T. cruzi heat shock proteins we have characterized, reacting strongly in immunoblots with sera from infected mice. 相似文献
52.
Wong WW Doyle TC Cheung P Olson TM Reisler E 《Journal of muscle research and cell motility》2001,22(8):665-674
The molecular mechanisms by which different mutations in actin lead to distinct cardiomyopathies are unknown. Here, actin
mutants corresponding to α-cardiac actin mutations causing hypertrophic cardiomyopathy [(HCM) P164A and A331P] and dilated
cardiomyopathy [(DCM) R312H and E361G] were expressed in yeast and purified for in vitro functional studies. While P164A appeared unaltered compared to wild-type (WT) actin, A331P function was impaired. A331P showed
reduced stability in circular dichroism melting experiments; its monomer unfolding transition was 10°C lower compared to WT
actin. Additionally, in vitro filament formation was hampered, and yeast cell cultures were temperature sensitive, implying perturbations in actin–actin
interactions. Filament instability of the A331P mutant actin could lead to actomyosin dysfunction observed in HCM. Yeast strains
harboring the R312H mutation did not grow well in culture, suggesting that cell viability is compromised. The E361G substitution
is located at an α-actinin binding region where the actin filament is anchored. The mutant actin, though unaltered in the
in vitro motility and standard actomyosin functions, had a threefold reduction in α-actinin binding. This could result in impairment
of force-transduction in muscle fibers, and a DCM phenotype.
This revised version was published online in July 2006 with corrections to the Cover Date. 相似文献
53.
Biological activities of monoclonal antibodies to Mycoplasma pneumoniae membrane glycolipids. 下载免费PDF全文
D K Chandler L D Olson J G Kenimer P G Probst S Rottem M W Grabowski M F Barile 《Infection and immunity》1989,57(4):1131-1136
A purified preparation of membranes was obtained by using a unique method of treating Mycoplasma pneumoniae with the ATPase inhibitor, diethylstilbestrol. This method was shown to yield highly purified membranes with little or no cytoplasmic contamination. These membranes were used to immunize mice for subsequent productions of monoclonal antibodies (MAbs). Hybridoma culture supernatants were screened by enzyme-linked immunosorbent assay with whole-cell M. pneumoniae and lipid extract antigens. Four stable MAbs were obtained and characterized. MAb CP3-46F5 reacted with a protein of a molecular weight of approximately 52,000 as determined by Western blot (immunoblot). MAbs CP3-50C2, CP3-53C5, and CP3-53C8 did not react with any antigens on Western blots but did bind to at least 10 distinct glycolipid bands as determined by orcinol staining on thin-layer chromatograms of M. pneumoniae lipid extracts. The MAbs did not react with similarly prepared lipid extracts from Mycoplasma genitalium, Mycoplasma neurolyticum, and Mycoplasma gallisepticum. These MAbs did not inhibit M. pneumoniae metabolism or attachment to WiDr cell cultures. The anti-glycolipid MAbs recognize determinants specific to M. pneumoniae, unlike polyclonal hyperimmune sera against M. pneumoniae, which cross-react with lipid extracts of M. genitalium. 相似文献
54.
55.
56.
57.
58.
CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia
Dianne Pulte Kim E Olson M Johan Broekman Naziba Islam Harold S Ballard Richard R Furman Ashley E Olson Aaron J Marcus 《Journal of translational medicine》2007,5(1):23
Background
Chronic lymphocytic leukemia (CLL) is characterized by accumulation of mature appearing lymphocytes and is rarely complicated by thrombosis. One possible explanation for the paucity of thrombotic events in these patients may be the presence of the ecto-nucleotidase CD39/NTDPase-1 on the surface of the malignant cells in CLL. CD39 is the major promoter of platelet inhibition in vivo via its metabolism of ADP to AMP. We hypothesize that if CD39 is observed on CLL cells, then patients with CLL may be relatively protected against platelet aggregation and recruitment and that CD39 may have other effects on CLL, including modulation of the disease, via its metabolism of ATP. 相似文献59.
Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs 总被引:6,自引:0,他引:6
C. A. Nosrat Andreas Tomac Barry J. Hoffer Lars Olson 《Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale》1997,115(3):410-422
Glial cell line-derived neurotrophic factor (GDNF) has recently been shown to signal by binding to GDNF receptor-alpha (GDNFR-α),
after which the GDNF-GDNFR-α associates with and activates the tyrosine kinase receptor Ret. We have localized Ret messenger
RNA (mRNA) in the developing and adult rodent and compared with to the expression of GDNF and GDNFR-α mRNA. Ret mRNA is strongly
expressed in dopamine neurons and α-motorneurons as well as in thalamus, ruber and occlumotor nuclei, the habenular complex,
septum, cerebellum, and brain stem nuclei. Ret mRNA was also found in several sensory systems, in ganglia, and in nonneuronal
tissues such as teeth and vibrissae. Very strong Ret mRNA signals are present in kidney and the gastrointestinal tract, where
Ret and GDNF mRNA expression patterns are precisely complementary. The presence of Ret protein was confirmed in adult dopamine
neurons using immunohistochemistry. GDNFR-α mRNA was strongly expressed in the developing and adult dopamine neurons. It was
also found in neurons in deep layers of cortex cerebri, in hippocampus, septum, the dentate gyrus, tectum, and the developing
spinal cord. In the kidney and the gastrointestinal tract, GDNFR-α mRNA and Ret mRNA distribution overlapped. Dorsal root
ganglia, cranial ganglia, and developing peripheral nerves were also positive. GDNFR-α was additionally found in sensory areas
and in developing teeth. Sensory areas included inner ear, eye, olfactory epithelium, and the vomeronasal organ, as well as
developing tongue papillae. The temporospatial pattern of expression of GDNFR-α mRNA did not always match that of Ret mRNA.
For instance, GDNFR-α mRNA was also found in the developing ventral striatum, including the olfactory tubercle, and in hippocampus.
These areas seemed devoid of Ret mRNA, suggesting that GDNFR-α might also have functions unrelated to Ret.
Received: 2 January 1997 / Accepted: 26 February 1997 相似文献
60.
Brilakis ES Olson LJ Berry GJ Daly RC Loisance D Zucker M Cooper LT 《ASAIO journal (American Society for Artificial Internal Organs : 1992)》2000,46(5):569-572
Giant cell myocarditis is a highly lethal disorder characterized by rapidly progressive congestive heart failure. The aim of this study was to describe the clinical course of patients with giant cell myocarditis who received a ventricular assist device. Patients with giant cell myocarditis were identified from the Multicenter Giant cell Myocarditis Registry. Bridging to cardiac transplantation in the giant cell myocarditis patients who received a ventricular assist device was compared with bridging in the general population of heart failure patients, as reported in the literature. Median posttransplantation survival for patients with giant cell myocarditis who received and did not receive ventricular assist devices was calculated by the Kaplan-Meier method and compared with use of the log-rank test. Nine patients with giant cell myocarditis who received ventricular assist devices were identified. Seven patients survived to transplantation, four were alive 30 days posttransplantation, and two survived to 1 year. The rate of successful bridging to transplantation in seven of nine patients (78%) is similar to that reported for other ventricular assist device recipients. Posttransplantation survival of 57% (4 of 7) at 30 days and 29% (2 of 7) at 1 year was significantly lower compared with 93% 1-year survival of the 30 patients with giant cell myocarditis who did not receive ventricular assist devices before transplantation (p<0.001). Ventricular assist devices can be an effective bridge to transplantation for patients with heart failure caused by giant cell myocarditis. Although their posttransplantation survival was poor in our series, a few patients had long-term survival. 相似文献